JEIL PHARMA HOLDINGS INC. Logo

JEIL PHARMA HOLDINGS INC.

Develops and distributes APIs, generics, and modified drugs, specializing in injections.

002620 | KO

Overview

Corporate Details

ISIN(s):
KR7002620003
LEI:
Country:
South Korea
Address:
서울특별시 서초구 사평대로 343, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jeil Pharma Holdings Inc. is a holding company that operates in the pharmaceutical industry. Through its subsidiaries, primarily Jeil Pharmaceutical Co., Ltd. (founded in 1959), the company manufactures and distributes a wide range of pharmaceutical products. Its business encompasses the production of active pharmaceutical ingredients (APIs), generic drugs, and incrementally modified drugs. The company's portfolio includes treatments across various therapeutic areas such as analgesic anti-inflammatories, antibiotics, anticoagulants, anti-diabetics, and gastrointestinal medicines. Jeil focuses on developing new synthetic processes and high-value products, with a specialization in injection medicines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-29 00:00
Governance Information
기업지배구조보고서공시
Korean 923.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.7 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 21.4 KB
2025-03-17 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.0 MB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 987.3 KB
2025-03-05 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 9.1 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 8.6 KB
2025-02-24 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 14.3 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.5 MB
2024-09-23 00:00
Governance Information
[기재정정]기업지배구조보고서공시
Korean 847.3 KB
2024-08-28 00:00
Interim Report
[기재정정]반기보고서 (2024.06)
Korean 1.4 MB
2024-08-14 00:00
Interim Report
반기보고서 (2024.06)
Korean 1.4 MB
2024-05-30 00:00
Governance Information
기업지배구조보고서공시
Korean 844.4 KB

Automate Your Workflow. Get a real-time feed of all JEIL PHARMA HOLDINGS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JEIL PHARMA HOLDINGS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JEIL PHARMA HOLDINGS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America
MRK
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN
Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America
MRUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.